Pulmonary vascular disease & thromboembolism
Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension: A Registry Report and Updated Meta-Analysis
Authors' conclusion
Anticoagulant use in PAH was not associated with overall survival in the nationwide registry. These results were supported by an updated meta-analysis.
Study context
- Population
- Patients diagnosed with pulmonary arterial hypertension (PAH), national French Pulmonary Hypertension Registry, 2009–2020
- Participants
- 1,597 patients
- Comparison
- Anticoagulants vs no anticoagulants
- Anticoagulantsn = 380
- Outcome
- Survival
Methodological detailspropensity score-based analysis, nationwide registry
- Propensity score-based analysis
- Nationwide registry
Pooled result
Survival (registry)
Hazard ratio
0.997
95% CI 0.84–1.18
P = 0.97
By group
Anticoagulants vs No anticoagulants
HR 0.997 (95% CI 0.84–1.18); P = 0.97
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Survival, updated meta-analysis of nationwide data sets — Anticoagulants vs No anticoagulants · overall PAH population | 0.98 (0.78–1.23) | |
| Survival, updated meta-analysis of nationwide data sets — Anticoagulants vs No anticoagulants · idiopathic/heritable PAH or PAH associated with anorexigens | 0.99 (0.79–1.25) | |
| Survival, updated meta-analysis of nationwide data sets — Anticoagulants vs No anticoagulants · PAH associated with connective tissue disease | 0.86 (0.52–1.42) | |
| 0.512Hazard ratio (log scale) |
- Survival, updated meta-analysis of nationwide data sets: 2 predefined subgroups
Survival, PAH subgroups within the registry
- Findings consistent across all PAH subgroups
Original publication
Association Between Anticoagulant Therapy and Survival in Pulmonary Arterial Hypertension: A Registry Report and Updated Meta-Analysis. J Am Coll Cardiol. Published 30 September 2025. doi:10.
Summarised from the published abstract; every number is checked against it